Search Results 491-500 of 14768 for anti-TNF drugs

  1. Antithyroid Agent (Oral Route, Rectal Route) Before Using - Mayo Clinic

    If you are taking a large dose, it may be necessary for you to stop breast-feeding during treatment. Drug Interactions. Although certain medicines should not be ...

  2. Tbo-Filgrastim (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Tbo-filgrastim is used to ...

  3. Anabolic Steroid (Oral Route, Parenteral Route) Side Effects - Mayo Clinic

    Tumors of the liver, liver cancer, or peliosis hepatis, a form of liver disease, have occurred during long-term, high-dose therapy with anabolic steroids.

  4. Testosterone (Buccal Route) Before Using - Mayo Clinic

    An alternative to this medication should be prescribed or you should stop breastfeeding while using this medicine. Drug Interactions. Although certain medicines ...

  5. New treatment option for early type 1 diabetes - Mayo Clinic

    According to findings published in The New England Journal of Medicine in 2023, teplizumab is an anti-CD3 antibody approved for people 8 years and older ...

  6. Calcipotriene (Topical Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Calcitrene; Dovonex; Sorilux. Descriptions.

  7. Tuberculin (Intradermal Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Aplisol; Tubersol. Descriptions. Tuberculin ...

  8. Infliximab-Abda (Intravenous Route) Proper Use - Mayo Clinic

    Ask your doctor if you have questions. You may also receive other medicines (eg, allergy medicine, fever medicine, steroids) to help prevent possible unwanted ...

  9. Mayo Clinic researchers identify cancer-fighting drugs that help morbidly obese mice to lose weight

    17 edition of Oncotarget. “We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only ...

  10. Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) - Mayo Clinic

    Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or ...